Home › NDC Lookup › RxCUI directory › RxCUI 1486981

Dapagliflozin 5 MG Oral Tablet [Farxiga] — RxCUI 1486981

RxNorm drug concept · Semantic branded drug
RxCUI 1486981 Semantic branded drug · SBD ● Current RxNorm concept 4 FDA products 9 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1486981
Official nameDapagliflozin 5 MG Oral Tablet [Farxiga]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asFarxiga 5 MG Oral Tablet
FDA products mapped4
Package NDCs mapped9
Reported Medicaid activity (SDUD)1,113,016 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Dapagliflozin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • No, it's used for more than just blood sugar control. Dapagliflozin is approved to help manage type 2 diabetes, but it's also used to reduce the risk of serious heart failure compl...
  • What is dapagliflozin actually used for — is it just for diabetes?
  • You can take it either way — with or without food. A high-fat meal may slow how quickly it absorbs slightly, but it doesn't change the overall amount that gets into your system. Ju...
  • Can I take this tablet with food, or does it have to be on an empty stomach?
📖 Read our full Dapagliflozin guide →

🕸️ Concept Web — How Dapagliflozin 5 MG Oral Tablet [Farxiga] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Dapagliflozin 5 MG Oral Tablet [Farxiga] RxCUI 1486981

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Dapagliflozin 1488564
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Farxiga 1486972
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Dapagliflozin Oral Tablet 1488568
    • Dapagliflozin Oral Product 1488566
    • Dapagliflozin Pill 1488567
    • Dapagliflozin Oral Tablet [Farxiga] 1534343
    • Farxiga Oral Product 1486975
    • Farxiga Pill 1486976
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Dapagliflozin 5 MG Oral Tablet SCD · 1488574
  • Dapagliflozin 5 MG SCDC · 1488573
  • Dapagliflozin Oral Tablet SCDF · 1488568
  • Dapagliflozin Oral Product SCDG · 1488566
  • Dapagliflozin Pill SCDG · 1488567

Brand-Name Concepts

  • Dapagliflozin 5 MG [Farxiga] SBDC · 1534344
  • Dapagliflozin Oral Tablet [Farxiga] SBDF · 1534343
  • Farxiga Oral Product SBDG · 1486975
  • Farxiga Pill SBDG · 1486976
  • Farxiga BN · 1486972

📦 FDA Products & Package NDCs

4 products · 9 package NDCs
9 package NDCs map to RxCUI 1486981 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00310-6205-30 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0310-6205-30) FARXIGA AstraZeneca Pharmaceuticals LP 2015-02-02
00310-6205-90 90 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0310-6205-90) FARXIGA AstraZeneca Pharmaceuticals LP 2024-03-18
00310-6205-95 1 BLISTER PACK in 1 CARTON (0310-6205-95) / 7 TABLET, FILM... FARXIGA AstraZeneca Pharmaceuticals LP 2015-02-02
00310-6210-30 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0310-6210-30) FARXIGA AstraZeneca Pharmaceuticals LP 2015-01-05
00310-6210-39 3 BLISTER PACK in 1 CARTON (0310-6210-39) / 10 TABLET, FILM... FARXIGA AstraZeneca Pharmaceuticals LP 2022-12-02
00310-6210-90 90 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0310-6210-90) FARXIGA AstraZeneca Pharmaceuticals LP 2024-03-18
00310-6210-95 1 BLISTER PACK in 1 CARTON (0310-6210-95) / 7 TABLET, FILM... FARXIGA AstraZeneca Pharmaceuticals LP 2015-01-05
55154-6933-08 840 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (55154-6933-8) FARXIGA Cardinal Health 107, LLC 2015-01-05
70518-4614-00 50 POUCH in 1 BOX (70518-4614-0) / 1 TABLET, FILM COATED in... FARXIGA REMEDYREPACK INC. 2026-04-23
Observed labelers: AstraZeneca Pharmaceuticals LP (7) · Cardinal Health 107, LLC (1) · REMEDYREPACK INC. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.